|
1
|
Kudo M: The 2008 Okuda lecture: Management
of hepatocellular carcinoma: from surveillance to molecular
targeted therapy. J Gastroenterol Hepatol. 25:439–452. 2010.
|
|
2
|
Yuen MF, Hou JL and Chutaputti A: Asia
Pacific Working Party on Prevention of Hepatocellular Carcinoma:
Hepatocellular carcinoma in the Asia pacific region. J
Gastroenterol Hepatol. 24:346–353. 2009.
|
|
3
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: an update. Hepatology. 53:1020–1022.
2011.
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, et al: SHARP Investigators Study Group:
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.
359:378–390. 2008.
|
|
5
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, et al: Efficacy and safety of sorafenib in patients in the
Asia-Pacific region with advanced hepatocellular carcinoma: a phase
III randomised, double-blind, placebo-controlled trial. Lancet
Oncol. 10:25–34. 2009.
|
|
6
|
Cheng HY, Wang X, Chen D, Xu AM and Jia
YC: The value and limitation of transcatheter arterial
chemoembolization in preventing recurrence of resected
hepatocellular carcinoma. World J Gastroenterol. 11:3644–3646.
2005.
|
|
7
|
Llovet JM, Real MI, Montaña X, Planas R,
Coll S, Aponte J, et al; Barcelona Liver Cancer Group. Arterial
embolisation or chemoembolisation versus symptomatic treatment in
patients with unresectable hepatocellular carcinoma: a randomised
controlled trial. Lancet. 359:1734–1739. 2002.
|
|
8
|
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM,
Poon RT, et al: Randomized controlled trial of transarterial
lipiodol chemoembolization for unresectable hepatocellular
carcinoma. Hepatology. 35:1164–1171. 2002.
|
|
9
|
Sergio A, Cristofori C, Cardin R, Pivetta
G, Ragazzi R, Baldan A, et al: Transcatheter arterial
chemoembolization (TACE) in hepatocellular carcinoma (HCC): the
role of angiogenesis and invasiveness. Am J Gastroenterol.
103:914–921. 2008.
|
|
10
|
Shim JH, Park JW, Kim JH, An M, Kong SY,
Nam BH, et al: Association between increment of serum VEGF level
and prognosis after transcatheter arterial chemoembolization in
hepatocellular carcinoma patients. Cancer Sci. 99:2037–2044.
2008.
|
|
11
|
Wilhelm SM, Adnane L, Newell P, et al:
Preclinical overview of sorafenib, a multikinase inhibitor that
targets both Raf and VEGF and PDGF receptor tyrosine kinase
signaling. Mol Cancer Ther. 7:3129–3140. 2008.
|
|
12
|
Cabrera R, Pannu DS, Caridi J, Firpi RJ,
Soldevila-Pico C, Morelli G, et al: The combination of sorafenib
with transarterial chemoembolisation for hepatocellular carcinoma.
Aliment Pharmacol Ther. 34:205–213. 2011.
|
|
13
|
Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM,
Gong GQ, et al: The efficacy of TACE combined sorafenib in advanced
stages hepatocellullar carcinoma. BMC Cancer. 12:2632012.
|
|
14
|
Sansonno D, Lauletta G, Russi S, Conteduca
V, Sansonno L and Dammacco F: Transarterial chemoembolization plus
sorafenib: a sequential therapeutic scheme for HCV-related
intermediate-stage hepatocellular carcinoma: a randomized clinical
trial. Oncologist. 17:359–366. 2012.
|
|
15
|
Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY,
Chen MS and Shi M: Transarterial chemoembolization for unresectable
hepatocellular carcinoma with portal vein tumor thrombosis: a
prospective comparative study. Ann Surg Oncol. 18:413–420.
2011.
|
|
16
|
Guan YS, He Q and Wang MQ: Transcatheter
arterial chemoembolization: history for more than 30 years. ISRN
Gastroenterol. 2012:4806502012.
|
|
17
|
Trotti A, Colevas AD, Setser A, et al:
CTCAE v3.0: development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003.
|
|
18
|
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR,
Bhagat N and Geschwind JF: Phase II trial of sorafenib combined
with concurrent transarterial chemoembolization with drug-eluting
beads for hepatocellular carcinoma. J Clin Oncol. 29:3960–3967.
2011.
|
|
19
|
Dufour JF, Hoppe H, Heim MH, Helbling B,
Maurhofer O, Szucs-Farkas Z, et al: Continuous administration of
sorafenib in combination with transarterial chemoembolization in
patients with hepatocellular carcinoma: results of a phase I study.
Oncologist. 15:1198–1204. 2010.
|
|
20
|
Kudo M, Imanaka K, Chida N, Nakachi K, Tak
WY, Takayama T, et al: Phase III study of sorafenib after
transarterial chemoembolisation in Japanese and Korean patients
with unresectable hepatocellular carcinoma. Eur J Cancer.
47:2117–2127. 2011.
|
